Basic Details
| Item | Value |
|---|---|
| Title | Alpine Biotech Edge: Paid Newsletter on Swiss/EU Pharma Catalysts |
| Type | Service |
| Difficulty | 25 |
| Ideal Capital | 1000 |
| ROI | 60% |
| ETA on ROI | 6 |
| Target Audience | Retail investors and finance professionals seeking actionable, small-cap biotech ideas |
| Target Countries | Switzerland, Germany, EU, UK, USA, and English-speaking global markets |
| Target Demographics | Ages 30-60, male and female, professionals with disposable income, interests in investing, biotech, and financial newsletters; readers of Substack/Seeking Alpha |
| Description | Launch a paid weekly newsletter analyzing Swiss and European pharma small-caps, starting with Basilea. Each issue covers one company: financials, pipeline catalysts (e.g., Fosmanogepix Phase-3), valuation, risks, and a model portfolio. Distribute via Substack or Beehiiv. Offer a free weekly teaser and a paid tier with full analysis, a catalyst calendar, and trade alerts. Build credibility by publishing detailed Basilea research tied to the H1 2026 report and raised guidance. Monetize subscriptions plus affiliate partnerships with brokers and data tools. |
| Monetization | Subscription at $15/month or $150/year; sponsored posts and affiliate links to brokers/data providers add revenue. Target 500 paid subscribers in year one. |
| Pros |
|
| Cons |
|